Journal
DRUG ADDICTION: RESEARCH FRONTIERS AND TREATMENT ADVANCES
Volume 1139, Issue -, Pages 63-69Publisher
BLACKWELL PUBLISHING
DOI: 10.1196/annals.1432.022
Keywords
glutamate cysteine lipase modifier (GCLM) subunit gene; methamphetamine-use disorder; schizophrenia; linkage disequilibrium; tagging SNPs
Categories
Funding
- Ministry of Education, Science, Sports and Culture
- Smoking Research Foundation
- Ministry of Health, Labor and Welfare
- Japan Health Sciences Foundation (Research on Health Sciences Focusing on Drug Innovation)
Ask authors/readers for more resources
A recent study showed a significant association between schizophrenia in European samples and the glutamate cysteine ligase modifier (GCLM) subunit gene, which is the key glutathione (GSH)-synthesizing enzyme. Since the symptoms of methamphetamine (METH)-induced psychosis are similar to those of schizophrenia, the GCLM gene is thought to be a good candidate gene for METH-use disorder or related disorders. To evaluate the association between the GCLM gene and METH-use disorder and schizophrenia, we conducted a case-control study of Japanese subjects (METH-use disorder, 185 cases; schizophrenia, 742 cases; and controls, 819). Four SNPs (2 SNPs from an original report and JSNP database, and 2 tagging SNPs from HapMap database) in the GCLM gene were examined in this association analysis; one SNP showed an association with both METH-use disorder and METH-induced psychosis. After Bonferroni's correction for multiple testing, however, this significance disappeared. No significant association was found with schizophrenia. Our findings suggest that a common genetic variation in the GCLM gene might not contribute to the risk of METH-use disorder and schizophrenia in the Japanese population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available